Plunkett Research Online: Chiasma

CHIASMA (CHMA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Chiasma Inc is a biopharmaceutical company that focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being .....



Chiasma
Ticker: CHMA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617 928-5300
Fax:
Address: 140 Kendrick Street
Building C East
Needham, MA 02494 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
ContactsDescription

Raj KannanCEO/Director
Mark FitzpatrickCFO/President
See More
Chiasma Inc is a biopharmaceutical company that focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being .....See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: